SMMT
Summit Therapeutics Inc.
SMMT
Summit Therapeutics Inc.
Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the pas
Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically sign
NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) brea